

# Jeffrey Aronson

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7726528/jeffrey-aronson-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

289  
papers

14,999  
citations

55  
h-index

117  
g-index

368  
ext. papers

18,088  
ext. citations

5.9  
avg, IF

6.99  
L-index

#	Paper	IF	Citations
289	Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity.. <i>Drug Safety</i> , <b>2022</b> , 45, 137	5.1	1
288	Sales of Over-the-Counter Products Containing Codeine in 31 Countries, 2013-2019: A Retrospective Observational Study.. <i>Drug Safety</i> , <b>2022</b> , 45, 237	5.1	0
287	When I use a word . . . . St Bartholomew-onomastics and reputation.. <i>BMJ, The</i> , <b>2022</b> , 376, o370	5.9	0
286	Global, regional, and national consumption of controlled opioids: a cross-sectional study of 214 countries and non-metropolitan territories.. <i>British Journal of Pain</i> , <b>2022</b> , 16, 34-40	2.1	2
285	When I use a word . . . . Listening to the patient.. <i>BMJ, The</i> , <b>2022</b> , 376, o646	5.9	1
284	Blood pressure meta-analysis highlights an implementation gap.. <i>Lancet, The</i> , <b>2022</b> , 399, 1379-1380	4.0	1
283	When I use a word . . . . Remembrance of things past.. <i>BMJ, The</i> , <b>2022</b> , 377, o873	5.9	0
282	Artificial Intelligence in Pharmacovigilance: An Introduction to Terms, Concepts, Applications, and Limitations.. <i>Drug Safety</i> , <b>2022</b> , 45, 407-418	5.1	1
281	When I use a word . . . . The efficiency paradox. <i>BMJ, The</i> , <b>2021</b> , 375, n2712	5.9	1
280	When I use a word . . . . Examining the efficiency paradox. <i>BMJ, The</i> , <b>2021</b> , 375, n2856	5.9	
279	When I use a word . . . . Taking therapeutic care. <i>BMJ, The</i> , <b>2021</b> , 375, n3010	5.9	0
278	Deaths from cardiovascular disease involving anticoagulants: a systematic synthesis of coroners' case reports. <i>BJGP Open</i> , <b>2021</b> ,	3.1	3
277	The Oxford Catalogue of Opioids: A systematic synthesis of opioid drug names and their pharmacology. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 3790-3812	3.8	3
276	The problem of look-alike, sound-alike name errors: Drivers and solutions. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 386-394	3.8	8
275	Forgotten Primodos story and the roles of general practitioners. <i>BMJ Evidence-Based Medicine</i> , <b>2021</b> , 26, 79-81	2.7	1
274	The use of mechanistic reasoning in assessing coronavirus interventions. <i>Journal of Evaluation in Clinical Practice</i> , <b>2021</b> , 27, 684-693	2.5	3
273	A systematic literature review of LASA error interventions. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 336-351	3.8	0

272	Coroners' concerns to prevent harms: a series of coroners' case reports to serve patient safety and educate the public, clinicians and policy-makers. <i>BMJ Evidence-Based Medicine</i> , <b>2021</b> , 26, 37-38	2.7	8
271	Analysis of reports of unintended pregnancies associated with the combined use of non-enzyme-inducing antibiotics and hormonal contraceptives. <i>BMJ Evidence-Based Medicine</i> , <b>2021</b> , 26, 112-113	2.7	2
270	Dealing with categorical risk data when extracting data for meta-analysis. <i>BMJ Evidence-Based Medicine</i> , <b>2021</b> , 26, 43-45	2.7	1
269	Combining and converting groups when extracting data for meta-analysis. <i>BMJ Evidence-Based Medicine</i> , <b>2021</b> , 26, 85-87	2.7	1
268	Summarising good practice guidelines for data extraction for systematic reviews and meta-analysis. <i>BMJ Evidence-Based Medicine</i> , <b>2021</b> , 26, 88-90	2.7	7
267	Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. <i>BMJ, The</i> , <b>2021</b> , 374, n1537 <sup>5.9</sup>	5.9	20
266	Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: a multi-method research programme. <i>Programme Grants for Applied Research</i> , <b>2021</b> , 9, 1-218	1.5	
265	Preventable deaths from SARS-CoV-2 in England and Wales: a systematic case series of coroners' reports during the COVID-19 pandemic.. <i>BMJ Evidence-Based Medicine</i> , <b>2021</b> ,	2.7	2
264	Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 2114-2122	3.8	14
263	Single screening or double screening for study selection in systematic reviews?. <i>BMJ Evidence-Based Medicine</i> , <b>2020</b> , 25, 149-150	2.7	3
262	Relation between opioid consumption and inclusion of opioids in 137 national essential medicines lists. <i>BMJ Global Health</i> , <b>2020</b> , 5,	6.6	8
261	Defining Aspects of Mechanisms: Evidence-Based Mechanism (Evidence for a Mechanism), Mechanism-Based Evidence (Evidence from a Mechanism), and Mechanistic Reasoning. <i>Boston Studies in the Philosophy and History of Science</i> , <b>2020</b> , 3-38	0.2	3
260	Medical Devices: Classification and Analysis of Faults Leading to Harms. <i>Drug Safety</i> , <b>2020</b> , 43, 95-102	5.1	1
259	Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 646-667	3.8	9
258	Medical Devices: Definition, Classification, and Regulatory Implications. <i>Drug Safety</i> , <b>2020</b> , 43, 83-93	5.1	16
257	Extending anticoagulation treatment for unprovoked venous thromboembolism. <i>BMJ Evidence-Based Medicine</i> , <b>2020</b> , 25, 184-186	2.7	1
256	Key concepts for making informed choices. <i>Nature</i> , <b>2019</b> , 572, 303-306	50.4	13
255	Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis. <i>BMJ Open</i> , <b>2019</b> , 9, e030596	3	7

254	The British Pharmacological Society's WDM Paton Memorial Lecture 2019: How doctors were informed about pharmaceutical products through advertising in the British Medical Journal from 1955/6 to 1985/6. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 1901-1906	3.8	3
253	Single or dual antiplatelet therapy after a transient ischaemic attack or minor ischaemic stroke?. <i>BMJ Evidence-Based Medicine</i> , <b>2019</b> , 24, 196-197	2.7	
252	Susceptibility to adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2205-2212	3.8	14
251	Trends in kidney function testing in UK primary care since the introduction of the quality and outcomes framework: a retrospective cohort study using CPRD. <i>BMJ Open</i> , <b>2019</b> , 9, e028062	3	5
250	Comparison of essential medicines lists in 137 countries. <i>Bulletin of the World Health Organization</i> , <b>2019</b> , 97, 394-404C	8.2	35
249	Adverse events in people taking macrolide antibiotics versus placebo for any indication. <i>The Cochrane Library</i> , <b>2019</b> , 1, CD011825	5.2	35
248	STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery. <i>International Journal of Surgery</i> , <b>2019</b> , 72, 156-165	7.5	855
247	Withdrawn medicines included in the essential medicines lists of 136 countries. <i>PLoS ONE</i> , <b>2019</b> , 14, e0235429	3.7	4
246	Sodium valproate: who knew what and when? Cumulative meta-analysis gives extra insights. <i>BMJ Evidence-Based Medicine</i> , <b>2019</b> , 24, 127-129	2.7	2
245	Marketing medicines: charting the rise of modern therapeutics through a systematic review of adverts in UK medical journals (1950-1980). <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 1668-1685	3.8	6
244	Variation in diagnostic test requests and outcomes: a preliminary metric for OpenPathology.net. <i>Scientific Reports</i> , <b>2018</b> , 8, 4752	4.9	11
243	Overtesting and undertesting in primary care: a systematic review and meta-analysis. <i>BMJ Open</i> , <b>2018</b> , 8, e018557	3	49
242	Benefits and Harms in Pivotal Trials of Oral Centrally Acting Antiobesity Medicines: A Systematic Review and Meta-Analysis. <i>Obesity</i> , <b>2018</b> , 26, 513-521	8	3
241	Catalogue of bias: attrition bias. <i>BMJ Evidence-Based Medicine</i> , <b>2018</b> , 23, 21-22	2.7	50
240	Methods for meta-analysis of pharmacodynamic dose-response data with application to multi-arm studies of alogliptin. <i>Statistical Methods in Medical Research</i> , <b>2018</b> , 27, 564-578	2.3	4
239	Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review. <i>Expert Opinion on Drug Safety</i> , <b>2018</b> , 17, 63-72	4.1	8
238	A word about evidence: 'rapid reviews' or 'restricted reviews'?. <i>BMJ Evidence-Based Medicine</i> , <b>2018</b> , 23, 204-205	2.7	7
237	Diagnostic test guidelines based on high-quality evidence had greater rates of adherence: a meta-epidemiological study. <i>Journal of Clinical Epidemiology</i> , <b>2018</b> , 103, 40-50	5.7	9

236	A brief history of clinical evidence updates and bibliographic databases. <i>Journal of the Royal Society of Medicine</i> , <b>2018</b> , 111, 292-301	2.3	2
235	Oral hormone pregnancy tests and the risks of congenital malformations: a systematic review and meta-analysis. <i>F1000Research</i> , <b>2018</b> , 7, 1725	3.6	9
234	Practice variation in the use of tests in UK primary care: a retrospective analysis of 16 million tests performed over 3.3 million patient years in 2015/16. <i>BMC Medicine</i> , <b>2018</b> , 16, 229	11.4	11
233	Temporal trends in use of tests in UK primary care, 2000-15: retrospective analysis of 250 million tests. <i>BMJ, The</i> , <b>2018</b> , 363, k4666	5.9	55
232	Examining the 'psychopharmacology revolution' (1950-1980) through the advertising of psychoactive drugs in the British Medical Journal. <i>Journal of Psychopharmacology</i> , <b>2018</b> , 32, 1056-1066	4.6	4
231	The use of mechanistic evidence in drug approval. <i>Journal of Evaluation in Clinical Practice</i> , <b>2018</b> , 24, 1166-1176	1.3	13
230	Reduced Salt Intake for Heart Failure: A Systematic Review. <i>JAMA Internal Medicine</i> , <b>2018</b> , 178, 1693-1700	1.5	34
229	What is a 'complex systematic review'? Criteria, definition, and examples. <i>BMJ Evidence-Based Medicine</i> , <b>2018</b> , 23, 127-130	2.7	4
228	Redefining rapid reviews: a flexible framework for restricted systematic reviews. <i>BMJ Evidence-Based Medicine</i> , <b>2018</b> , 23, 201-203	2.7	54
227	Defining 'nutraceuticals': neither nutritious nor pharmaceutical. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 8-19	3.8	105
226	Poor medication adherence in clinical trials: consequences and solutions. <i>Nature Reviews Drug Discovery</i> , <b>2017</b> , 16, 149-150	64.1	39
225	CARE guidelines for case reports: explanation and elaboration document. <i>Journal of Clinical Epidemiology</i> , <b>2017</b> , 89, 218-235	5.7	470
224	Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification. <i>Drug Safety</i> , <b>2017</b> , 40, 431-441	5.1	3
223	Biomarkers-A General Review. <i>Current Protocols in Pharmacology</i> , <b>2017</b> , 76, 9.23.1-9.23.17	4.1	86
222	The STROCSS statement: Strengthening the Reporting of Cohort Studies in Surgery. <i>International Journal of Surgery</i> , <b>2017</b> , 46, 198-202	7.5	662
221	Post-marketing drug withdrawals: Pharmacovigilance success, regulatory problems. <i>Therapie</i> , <b>2017</b> , 72, 555-561	3.8	9
220	Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 1328-1337	2.6	2
219	Unlicensed and off-label uses of medicines: definitions and clarification of terminology. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 2615-2625	3.8	32

218	Trials of transvaginal mesh devices for pelvic organ prolapse: a systematic database review of the US FDA approval process. <i>BMJ Open</i> , <b>2017</b> , 7, e017125	3	43
217	Ten essential papers for the practice of evidence-based medicine. <i>BMJ Evidence-Based Medicine</i> , <b>2017</b> , 22, 202-204	2.7	4
216	Short- and medium-term effects of light to moderate alcohol intake on glycaemic control in diabetes mellitus: a systematic review and meta-analysis of randomized trials. <i>Diabetic Medicine</i> , <b>2017</b> , 34, 604-611	3.5	8
215	Preferred reporting of case series in surgery; the PROCESS guidelines. <i>International Journal of Surgery</i> , <b>2016</b> , 36, 319-323	7.5	311
214	Inhibiting the proton pump: mechanisms, benefits, harms, and questions. <i>BMC Medicine</i> , <b>2016</b> , 14, 172	11.4	11
213	Nominal ISOMERs (Incorrect Spellings Of Medicines Eluding Researchers)-variants in the spellings of drug names in PubMed: a database review. <i>BMJ, The</i> , <b>2016</b> , 355, i4854	5.9	3
212	Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , <b>2016</b> , 30, 495-553	4.6	468
211	Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis. <i>Critical Reviews in Toxicology</i> , <b>2016</b> , 46, 477-89	5.7	54
210	How a VOICE for clinical pharmacology turns into a RECIPE for its development. <i>Translational and Clinical Pharmacology</i> , <b>2016</b> , 24, 1	2	0
209	"Collaborative care" is preferable to "patient centred care". <i>BMJ, The</i> , <b>2016</b> , 353, i2926	5.9	6
208	Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review. <i>BMC Medicine</i> , <b>2016</b> , 14, 191	11.4	73
207	Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. <i>BMC Medicine</i> , <b>2016</b> , 14, 10	11.4	242
206	Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP). <i>Drug Safety</i> , <b>2016</b> , 39, 421-32	5.1	15
205	The SCARE Statement: Consensus-based surgical case report guidelines. <i>International Journal of Surgery</i> , <b>2016</b> , 34, 180-186	7.5	1507
204	The law of mass action and the pharmacological concentration-effect curve: resolving the paradox of apparently non-dose-related adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 56-61	3.8	15
203	Cato Guldberg and Peter Waage, the history of the Law of Mass Action, and its relevance to clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 52-5	3.8	11
202	Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis. <i>BMC Medicine</i> , <b>2015</b> , 13, 26	11.4	37
201	Quantifying the effects of diuretics and $\beta$ -adrenoceptor blockers on glycaemic control in diabetes mellitus - a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 79, 733-43	3.8	30

200	Medication errors detected in non-traditional databases: types of errors in methotrexate dosing as listed in four different Danish registers. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 1375-9	2.8	10
199	Pycnodysostosis and the making of an artist. <i>Gene</i> , <b>2015</b> , 555, 59-62	3.8	8
198	Adverse events in patients taking macrolide antibiotics versus placebo for any indication. <i>The Cochrane Library</i> , <b>2015</b> ,	5.2	11
197	Photosensitivity reactions and skin tumours associated with voriconazole. <i>Adverse Drug Reaction Bulletin</i> , <b>2015</b> , 290, 1119-1122	0.7	
196	Toward standardized reporting of drug interactions: the READI checklist for anecdotal reports. <i>Expert Review of Clinical Pharmacology</i> , <b>2015</b> , 8, 399-409	3.8	3
195	Patient Safety in Medication Nomenclature: Orthographic and Semantic Properties of International Nonproprietary Names. <i>PLoS ONE</i> , <b>2015</b> , 10, e0145431	3.7	8
194	Checklist for standardized reporting of drug-drug interaction management guidelines. <i>European Journal of Clinical Pharmacology</i> , <b>2014</b> , 70, 313-8	2.8	16
193	The need for randomization in animal trials: an overview of systematic reviews. <i>PLoS ONE</i> , <b>2014</b> , 9, e98856	5.6	147
192	Medical eponyms: taxonomies, natural history, and the evidence. <i>BMJ, The</i> , <b>2014</b> , 349, g7586	5.9	12
191	Case Reports as Evidence in Pharmacovigilance <b>2014</b> , 121-137		6
190	Management of pain during injection of propofol. <i>Adverse Drug Reaction Bulletin</i> , <b>2014</b> , 287, 1107-1110	0.7	0
189	The adverse effects of nitrous oxide. <i>Adverse Drug Reaction Bulletin</i> , <b>2014</b> , 285, 1099-1102	0.7	2
188	Towards a single VOICE for European clinical pharmacology: proposals for future developments. <i>European Journal of Clinical Pharmacology</i> , <b>2013</b> , 69, 1981-4	2.8	2
187	Distinguishing hazards and harms, adverse drug effects and adverse drug reactions : implications for drug development, clinical trials, pharmacovigilance, biomarkers, and monitoring. <i>Drug Safety</i> , <b>2013</b> , 36, 147-53	5.1	20
186	All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database. <i>Diabetes Care</i> , <b>2013</b> , 36, 2366-71	14.6	94
185	David Grahame Grahame-Smith: clinical pharmacologist. 1933-2011. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 73, 830-2	3.8	
184	A new taxonomy for describing and defining adherence to medications. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 73, 691-705	3.8	910
183	Finding a VOICE for UK clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 73, 843-5	3.8	3

182	Research priorities in biomarkers and surrogate end-points. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 73, 900-7	3.8	17
181	Monitoring drug therapy. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 73, 917-23	3.8	21
180	From basic to clinical neuropharmacology: targetophilia or pharmacodynamics?. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 73, 959-67	3.8	4
179	Balanced prescribing - principles and challenges. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 74, 566-73	3.8	21
178	Selected national pharmacovigilance websites: an analysis of contents. <i>Drug Safety</i> , <b>2012</b> , 35, 141-8	5.1	2
177	Defining 'surveillance' in drug safety. <i>Drug Safety</i> , <b>2012</b> , 35, 347-57	5.1	15
176	Paradoxical and bidirectional drug effects. <i>Drug Safety</i> , <b>2012</b> , 35, 173-89	5.1	33
175	Defining rewardable innovation in drug therapy. <i>Nature Reviews Drug Discovery</i> , <b>2012</b> , 11, 253-4	64.1	35
174	What do clinical pharmacologists do? A questionnaire survey of senior UK clinical pharmacologists. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 73, 161-9	3.8	15
173	When I use a word ... Innovations--'The Births of Time'. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2012</b> , 105, 1037-9	2.7	
172	Evaluation of pharmacological evidence for forensic purposes. <i>International Journal of Risk and Safety in Medicine</i> , <b>2012</b> , 24, 3-12	1.6	
171	A new taxonomy for describing and defining adherence to medications <b>2012</b> , 73, 691		30
170	Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy. <i>PLoS ONE</i> , <b>2011</b> , 6, e18578	3.7	14
169	Integrating pharmacology and clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , <b>2011</b> , 71, 787-790	3.8	4
168	Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial. <i>PLoS Medicine</i> , <b>2011</b> , 8, e1000435	11.6	122
167	Clinical pharmacology and therapeutics in the UK--a great instauration. <i>British Journal of Clinical Pharmacology</i> , <b>2010</b> , 69, 111-7	3.8	14
166	A manifesto for clinical pharmacology from principles to practice. <i>British Journal of Clinical Pharmacology</i> , <b>2010</b> , 70, 3-13	3.8	30
165	Evidence-based mechanistic reasoning. <i>Journal of the Royal Society of Medicine</i> , <b>2010</b> , 103, 433-41	2.3	60



164	A systematic review and empirical analysis of the relation between dose and duration of drug action. <i>Journal of Clinical Pharmacology</i> , <b>2010</b> , 50, 17-26	2.9	6
163	Preventability of drug-related harms - part I: a systematic review. <i>Drug Safety</i> , <b>2010</b> , 33, 985-94	5.1	44
162	Preventability of drug-related harms - part II: proposed criteria, based on frameworks that classify adverse drug reactions. <i>Drug Safety</i> , <b>2010</b> , 33, 995-1002	5.1	25
161	Reducing prescription errors. <i>Lancet, The</i> , <b>2010</b> , 375, 461-2	4.0	2
160	EIDOS: a mechanistic classification of adverse drug effects. <i>Drug Safety</i> , <b>2010</b> , 33, 15-23	5.1	19
159	NICE and new: appraising innovation. <i>BMJ, The</i> , <b>2010</b> , 340, b5493	5.9	32
158	Medication errors: what they are, how they happen, and how to avoid them. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2009</b> , 102, 513-21	2.7	132
157	From prescription-only to over-the-counter medicines ('PoM to P'): time for an intermediate category. <i>British Medical Bulletin</i> , <b>2009</b> , 90, 63-9	5.4	15
156	Medication errors: problems and recommendations from a consensus meeting. <i>British Journal of Clinical Pharmacology</i> , <b>2009</b> , 67, 592-8	3.8	35
155	Medication errors: definitions and classification. <i>British Journal of Clinical Pharmacology</i> , <b>2009</b> , 67, 599-604	4.8	189
154	A strategy for regulatory action when new adverse effects of a licensed product emerge. <i>Drug Safety</i> , <b>2009</b> , 32, 91-8	5.1	9
153	Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions. <i>Drug Safety</i> , <b>2009</b> , 32, 99-110	5.1	83
152	The UK's NHS and pharma: need for more clinical pharmacologists. <i>Lancet, The</i> , <b>2009</b> , 373, 1251-2	4.0	6
151	Evaluation and stages of surgical innovations. <i>Lancet, The</i> , <b>2009</b> , 374, 1089-96	4.0	374
150	Patent medicines and secret remedies. <i>BMJ, The</i> , <b>2009</b> , 339, b5415	5.9	8
149	Clinical pharmacology--providing tools and expertise for translational medicine. <i>British Journal of Clinical Pharmacology</i> , <b>2008</b> , 65, 154-7	3.8	13
148	Publishing histories of adverse reactions to medicaments anecdotally: the PHARMA guidelines for reporting suspected adverse drug reactions. <i>Drug Safety</i> , <b>2008</b> , 31, 355-6; author reply 356-7	5.1	4
147	Something new every day: defining innovation and innovativeness in drug therapy. <i>Journal of Ambulatory Care Management</i> , <b>2008</b> , 31, 65-8	0.8	12

146	The diagnosis of art: Valentin le Bossard and Ehlers-Danlos syndrome. <i>Journal of the Royal Society of Medicine</i> , <b>2007</b> , 100, 193-4	2.3	2
145	Adverse drug reactions--no farewell to harms. <i>British Journal of Clinical Pharmacology</i> , <b>2007</b> , 63, 131-5	3.8	12
144	Editors' review of 2006 and the BJCP prize. <i>British Journal of Clinical Pharmacology</i> , <b>2007</b> , 63, 1-4	3.8	1
143	Communicating information about drug interactions. <i>British Journal of Clinical Pharmacology</i> , <b>2007</b> , 63, 637-639	3.8	19
142	Time to abandon the term patient concordance. <i>British Journal of Clinical Pharmacology</i> , <b>2007</b> , 64, 711-713	3.8	10
141	Editors' Report for 2006. <i>British Journal of Clinical Pharmacology</i> , <b>2007</b> , 64, 253-254	3.8	78
140	Old drugs--new uses. <i>British Journal of Clinical Pharmacology</i> , <b>2007</b> , 64, 563-5	3.8	69
139	The diagnosis of art: Caravaggio's jaundiced Bacchus. <i>Journal of the Royal Society of Medicine</i> , <b>2007</b> , 100, 429-30	2.3	3
138	Give a drug a good name. <i>Lancet, The</i> , <b>2007</b> , 369, 1326-1328	4.0	2
137	Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore. <i>Drug Safety</i> , <b>2007</b> , 30, 645-55	5.1	55
136	Case reports of suspected adverse drug reactions--systematic literature survey of follow-up. <i>BMJ, The</i> , <b>2006</b> , 332, 335-9	5.9	56
135	Anecdotes that provide definitive evidence. <i>BMJ, The</i> , <b>2006</b> , 333, 1267-9	5.9	109
134	Clarification of terminology in medication errors: definitions and classification. <i>Drug Safety</i> , <b>2006</b> , 29, 1011-22	5.1	144
133	The Diagnosis of Art: Melancholy and the Portrait of Dr Gachet. <i>Journal of the Royal Society of Medicine</i> , <b>2006</b> , 99, 373-374	2.3	3
132	The Diagnosis of Art: Exophthalmos. Gustave Doré's Ogre. <i>Journal of the Royal Society of Medicine</i> , <b>2006</b> , 99, 421-421	2.3	1
131	The Diagnosis of Art: Diastrophic Dysplasia and Hephaistos. <i>Journal of the Royal Society of Medicine</i> , <b>2006</b> , 99, 584-585	2.3	
130	The Diagnosis of Art: Arthrogryposis and Ribera's The Clubfoot. <i>Journal of the Royal Society of Medicine</i> , <b>2006</b> , 99, 321-322	2.3	5
129	The Diagnosis of Art: Rachmaninov's Hand Span. <i>Journal of the Royal Society of Medicine</i> , <b>2006</b> , 99, 529-530	2.3	1

128	The diagnosis of art: melancholy and the portrait of Dr. Gachet. <i>Journal of the Royal Society of Medicine</i> , <b>2006</b> , 99, 373-4	2.3	3
127	The diagnosis of art: exophthalmos--Gustave Doré's ogre. <i>Journal of the Royal Society of Medicine</i> , <b>2006</b> , 99, 421	2.3	2
126	The Doctor in Literature: Satisfaction or Resentment?. <i>Health Expectations</i> , <b>2006</b> , 9, 196-197	3.7	78
125	Today's science, tomorrow's medicines. <i>British Journal of Clinical Pharmacology</i> , <b>2006</b> , 61, 1-4	3.8	78
124	Medicines and the media. <i>British Journal of Clinical Pharmacology</i> , <b>2006</b> , 61, 121-122	3.8	78
123	Rare diseases and orphan drugs. <i>British Journal of Clinical Pharmacology</i> , <b>2006</b> , 61, 243-5	3.8	72
122	Editors' Report 2005. <i>British Journal of Clinical Pharmacology</i> , <b>2006</b> , 61, 492-493	3.8	78
121	Clinical Pharmacology: Past, Present, and Future. <i>British Journal of Clinical Pharmacology</i> , <b>2006</b> , 61, 647-649	3.8	13
120	The NSAID roller coaster: more about rofecoxib. <i>British Journal of Clinical Pharmacology</i> , <b>2006</b> , 62, 257-9	3.8	6
119	Polypharmacy, appropriate and inappropriate. <i>British Journal of General Practice</i> , <b>2006</b> , 56, 484-5	1.6	22
118	Open access publishing: too much oxygen?. <i>BMJ, The</i> , <b>2005</b> , 330, 759	5.9	5
117	Clarification of terminology in drug safety. <i>Drug Safety</i> , <b>2005</b> , 28, 851-70	5.1	149
116	Adjusting therapeutic dosage regimens to optimise the balance of benefit to harm. <i>Clinical Medicine</i> , <b>2005</b> , 5, 16-9	1.9	3
115	Oxford Handbook of Practical Drug Therapy <b>2005</b> ,		3
114	Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions. <i>Journal of Evaluation in Clinical Practice</i> , <b>2005</b> , 11, 195-208	2.5	19
113	National differences in publishing papers on adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , <b>2005</b> , 59, 108-11	3.8	11
112	Internationality. <i>British Journal of Clinical Pharmacology</i> , <b>2005</b> , 59, 1-4	3.8	1
111	Editors' Report 2004. <i>British Journal of Clinical Pharmacology</i> , <b>2005</b> , 60, 5-6	3.8	78

110	One hundred years of atrial fibrillation. <i>British Journal of Clinical Pharmacology</i> , <b>2005</b> , 60, 345-6	3.8	4
109	Prescribing statins. <i>British Journal of Clinical Pharmacology</i> , <b>2005</b> , 60, 457-8	3.8	4
108	Structural features of phenol derivatives determining potency for activation of chloride currents via alpha(1) homomeric and alpha(1)beta heteromeric glycine receptors. <i>British Journal of Pharmacology</i> , <b>2005</b> , 145, 916-25	8.6	11
107	Drug development: more science, more education. <i>British Journal of Clinical Pharmacology</i> , <b>2005</b> , 59, 377-8	3.8	8
106	The British Journal of Clinical Pharmacology Editors' Report for 2003. <i>British Journal of Clinical Pharmacology</i> , <b>2004</b> , 57, 538-539	3.8	78
105	On Being 30. <i>British Journal of Clinical Pharmacology</i> , <b>2004</b> , 57, 1-5	3.8	5
104	In defence of polypharmacy. <i>British Journal of Clinical Pharmacology</i> , <b>2004</b> , 57, 119-20	3.8	42
103	Drug interactions-information, education, and the British National Formulary. <i>British Journal of Clinical Pharmacology</i> , <b>2004</b> , 57, 371-2	3.8	10
102	On the waterfront [the breadth and depth of clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , <b>2004</b> , 57, 693-694	3.8	7
101	What is a clinical trial?. <i>British Journal of Clinical Pharmacology</i> , <b>2004</b> , 58, 1-3	3.8	52
100	Littluns and biguns. <i>British Journal of Clinical Pharmacology</i> , <b>2004</b> , 58, 117-118	3.8	3
99	Medicines regulation and clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , <b>2004</b> , 58, 569-570	3.8	2
98	A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. <i>British Journal of Clinical Pharmacology</i> , <b>2004</b> , 57, 616-21	3.8	47
97	An improved model for the binding of lidocaine and structurally related local anaesthetics to fast-inactivated voltage-operated sodium channels, showing evidence of cooperativity. <i>British Journal of Pharmacology</i> , <b>2004</b> , 141, 47-54	8.6	24
96	The British Journal of Clinical Pharmacology Editors' Report for 2002. <i>British Journal of Clinical Pharmacology</i> , <b>2003</b> , 55, 329-330	3.8	78
95	Features of this month's Journal. <i>British Journal of Clinical Pharmacology</i> , <b>2003</b> , 56, 475-476	3.8	78
94	Features of this month's Journal. <i>British Journal of Clinical Pharmacology</i> , <b>2003</b> , 56, 347-348	3.8	78
93	Features of this month's Journal. <i>British Journal of Clinical Pharmacology</i> , <b>2003</b> , 56, 247-248	3.8	78

92	Features of this month's Journal. <i>British Journal of Clinical Pharmacology</i> , <b>2003</b> , 55, 223-224	3.8	0
91	Features of this month's Journal. <i>British Journal of Clinical Pharmacology</i> , <b>2003</b> , 55, 327-328	3.8	78
90	Features of this month's Journal. <i>British Journal of Clinical Pharmacology</i> , <b>2003</b> , 55, 493-494	3.8	78
89	Features of this month's Journal. <i>British Journal of Clinical Pharmacology</i> , <b>2003</b> , 56, 141-142	3.8	1
88	Features of this month's Journal. <i>British Journal of Clinical Pharmacology</i> , <b>2003</b> , 56, 1-2	3.8	1
87	Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , <b>2003</b> , 361, 1935-8	4.0	96
86	Joining the DoTS: new approach to classifying adverse drug reactions. <i>BMJ, The</i> , <b>2003</b> , 327, 1222-5	5.9	147
85	Being wholistic. <i>Focus on Alternative and Complementary Therapies</i> , <b>2003</b> , 8, 381-382		
84	Adverse drug reactions: keeping up to date. <i>Fundamental and Clinical Pharmacology</i> , <b>2002</b> , 16, 49-56	3.1	34
83	Disco dancing. <i>Cytopathology</i> , <b>2002</b> , 13, 326-7	1.3	
82	Block of voltage-operated sodium channels by 2,6-dimethylphenol, a structural analogue of lidocaine's aromatic tail. <i>British Journal of Pharmacology</i> , <b>2002</b> , 137, 285-93	8.6	16
81	Forbidden fruit. <i>Nature Medicine</i> , <b>2001</b> , 7, 29-30	50.5	10
80	Structural requirements for voltage-dependent block of muscle sodium channels by phenol derivatives. <i>British Journal of Pharmacology</i> , <b>2001</b> , 132, 1916-24	8.6	28
79	Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. <i>BMC Medical Research Methodology</i> , <b>2001</b> , 1, 7	4.7	73
78	Francis Galton and the invention of terms for quantiles. <i>Journal of Clinical Epidemiology</i> , <b>2001</b> , 54, 1191-5.7		1
77	"Where name and image meet"--the argument for "adrenaline". <i>BMJ: British Medical Journal</i> , <b>2000</b> , 320, 506-9		28
76	Autopathography: the patient's tale. <i>BMJ: British Medical Journal</i> , <b>2000</b> , 321, 1599-602		41
75	Voltage-dependent blockade of normal and mutant muscle sodium channels by benzylalcohol. <i>British Journal of Pharmacology</i> , <b>2000</b> , 130, 1321-30	8.6	8

74	Inhibition of Na <sup>+</sup> /K <sup>(+)</sup> -ATPase may be one mechanism contributing to potassium efflux and cell shrinkage in CD95-induced apoptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , <b>2000</b> , 5, 153-63	5.4	70
73	Adverse drug reactions: definitions, diagnosis, and management. <i>Lancet, The</i> , <b>2000</b> , 356, 1255-9	40	1773
72	Medication errors, worse than a crime. <i>Lancet, The</i> , <b>2000</b> , 355, 947-8	40	52
71	Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. <i>Lancet, The</i> , <b>1998</b> , 352, 1590-3	40	37
70	Iatrogenic chest pain: a case of 5-fluorouracil cardiotoxicity. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>1996</b> , 89, 953-5	2.7	5
69	Effects of High External Concentrations of K <sup>+</sup> on 86Rb <sup>+</sup> Efflux in Human Platelets: Evidence for Na <sup>+</sup> /K <sup>+</sup> /2Cl <sup>-</sup> Co-Transport. <i>Clinical Science</i> , <b>1996</b> , 91, 725-731	6.5	3
68	Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. <i>British Journal of Clinical Pharmacology</i> , <b>1996</b> , 42, 423-429	3.8	81
67	Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. <i>British Journal of Clinical Pharmacology</i> , <b>1996</b> , 42, 423-9	3.8	68
66	Prolonged half-life of verapamil in a case of overdose: implications for therapy. <i>British Journal of Clinical Pharmacology</i> , <b>1995</b> , 39, 680-3	3.8	27
65	Confusion over similar drug names. Problems and solutions. <i>Drug Safety</i> , <b>1995</b> , 12, 155-60	5.1	16
64	The upregulation of Na <sup>+</sup> ,K <sup>(+)</sup> -ATPase pump numbers in lymphocytes from the first-degree unaffected relatives of patients with manic depressive psychosis in response to in vitro lithium and sodium ethacrynate. <i>Journal of Affective Disorders</i> , <b>1995</b> , 34, 33-9	6.6	19
63	What's in a brand name?. <i>BMJ: British Medical Journal</i> , <b>1994</b> , 308, 1140-1		5
62	Modelling circadian variation in the pharmacokinetics of non-steroidal anti-inflammatory drugs. <i>European Journal of Clinical Pharmacology</i> , <b>1993</b> , 45, 357-61	2.8	4
61	Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease. <i>Gut</i> , <b>1992</b> , 33, 1353-7	19.2	23
60	ABC of monitoring drug therapy. Cyclosporin. <i>BMJ: British Medical Journal</i> , <b>1992</b> , 305, 1491-4		9
59	ABC of monitoring drug therapy. Patient compliance. <i>BMJ: British Medical Journal</i> , <b>1992</b> , 305, 1009-11		30
58	Increase in Na <sup>+</sup> /K <sup>+</sup> pump numbers in vivo in healthy volunteers taking oral lithium carbonate and further upregulation in response to lithium in vitro. <i>British Journal of Clinical Pharmacology</i> , <b>1992</b> , 34, 535-40	3.8	7
57	Reversal of the effects of a low extracellular potassium concentration on the number and activity of Na <sup>+</sup> /K <sup>+</sup> pumps in an Epstein-Barr virus-transformed human lymphocyte cell line. <i>Biochemical Pharmacology</i> , <b>1992</b> , 43, 489-96	6	3

56	Potassium channels in nervous tissue. <i>Biochemical Pharmacology</i> , <b>1992</b> , 43, 11-4	6	50
55	Penicillin. <i>European Journal of Clinical Pharmacology</i> , <b>1992</b> , 42, 1-3	2.8	2
54	Altered in vitro adaptive responses of lymphocyte Na <sup>+</sup> ,K <sup>(+)</sup> -ATPase in patients with manic depressive psychosis. <i>Journal of Affective Disorders</i> , <b>1991</b> , 21, 199-206	6.6	40
53	The effect of nifedipine on the disposition of strontium gluconate used as a kinetic marker for calcium in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , <b>1991</b> , 32, 441-5	3.8	0
52	Intravenous strontium gluconate as a kinetic marker for calcium in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , <b>1991</b> , 31, 423-7	3.8	6
51	The effect of oral salbutamol on cation transport measured in vivo in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , <b>1990</b> , 30, 383-90	3.8	3
50	The measurement of transmembrane cation transport in vivo in acute manic illness. <i>British Journal of Psychiatry</i> , <b>1989</b> , 155, 501-4	5.4	6
49	A study of the transport of lithium across the erythrocyte membrane in vivo and of the effects of the ion transport inhibitors digoxin and dipyridamole. <i>British Journal of Clinical Pharmacology</i> , <b>1989</b> , 27, 749-56	3.8	5
48	The effect of lithium on cation transport measured in vivo in patients suffering from bipolar affective illness. <i>British Journal of Psychiatry</i> , <b>1989</b> , 155, 504-10	5.4	16
47	Standardization of symbols in clinical pharmacology. <i>European Journal of Clinical Pharmacology</i> , <b>1988</b> , 35, 1-7	2.8	58
46	Cation transport abnormalities in vivo in untreated essential hypertension. <i>Clinical Science</i> , <b>1986</b> , 70, 611-6	6.5	10
45	In vivo cation transport during short-term and long-term digoxin therapy. <i>British Journal of Clinical Pharmacology</i> , <b>1986</b> , 22, 27-30	3.8	1
44	The effects of serum, lithium, ethacrynic acid, and a low external concentration of potassium on specific [3H]-ouabain binding to human lymphocytes after incubation for 3 days. <i>British Journal of Clinical Pharmacology</i> , <b>1986</b> , 22, 275-9	3.8	14
43	The pharmacokinetics of L-tryptophan following its intravenous and oral administration. <i>British Journal of Clinical Pharmacology</i> , <b>1985</b> , 20, 317-21	3.8	8
42	A sensitive high-temperature electrothermal atomic absorption analysis for Rb <sup>+</sup> in erythrocytes and plasma of normal and hypertensive persons. <i>Clinical Chemistry</i> , <b>1985</b> , 31, 274-6	5.5	4
41	Measurement of specific [3H]-ouabain binding to different types of human leucocytes. <i>British Journal of Clinical Pharmacology</i> , <b>1984</b> , 18, 153-61	3.8	23
40	Cardiac glycosides and drugs used in dysrhythmias. <i>Side Effects of Drugs Annual</i> , <b>1984</b> , 8, 174-181	0.2	1
39	The role of the Na <sup>+</sup> , K <sup>+</sup> -ATPase in the regulation of vascular smooth-muscle contractility, and its relationship to essential hypertension. <i>Biochemical Society Transactions</i> , <b>1984</b> , 12, 943-5	5.1	6

38	Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction. <i>Clinical Pharmacokinetics</i> , <b>1983</b> , 8, 155-78	6.2	16
37	Indications for the measurement of plasma digoxin concentrations. <i>Drugs</i> , <b>1983</b> , 26, 230-42	12.1	30
36	Pharmacokinetic investigation of the interaction of azapropazone with phenytoin. <i>British Journal of Clinical Pharmacology</i> , <b>1983</b> , 15, 727-34	3.8	19
35	Cardiac glycosides and drugs used in dysrhythmias. <i>Side Effects of Drugs Annual</i> , <b>1983</b> , 7, 193-209	0.2	1
34	Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. <i>Gut</i> , <b>1982</b> , 23, 1081-7	19.2	132
33	The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. <i>British Journal of Clinical Pharmacology</i> , <b>1982</b> , 13, 523-8	3.8	93
32	Lack of effect of phenytoin on functions related to Na <sup>+</sup> ,K <sup>+</sup> -ATPase activity of the intact erythrocytes of epileptic patients. <i>British Journal of Clinical Pharmacology</i> , <b>1981</b> , 12, 79-81	3.8	1
31	Techniques for studying the pharmacodynamic effects of cardiac glycosides on patients' own erythrocytes during glycoside therapy. <i>Klinische Wochenschrift</i> , <b>1981</b> , 59, 1323-32		15
30	Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan. <i>British Journal of Clinical Pharmacology</i> , <b>1980</b> , 10, 603-10	3.8	40
29	Clinical pharmacokinetics of digoxin 1980. <i>Clinical Pharmacokinetics</i> , <b>1980</b> , 5, 137-49	6.2	80
28	The characteristics of the binding of 12- $\alpha$ -[3H]-digoxin to the membranes of intact human erythrocytes: relevance to digoxin therapy. <i>British Journal of Clinical Pharmacology</i> , <b>1979</b> , 8, 115-24	3.8	29
27	Changes in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation. <i>British Journal of Clinical Pharmacology</i> , <b>1979</b> , 8, 135-42	3.8	32
26	The acute changes seen in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy. <i>British Journal of Clinical Pharmacology</i> , <b>1979</b> , 8, 135-42	3.8	57
25	Tranlycypromine ('Parnate') overdose: measurement of tranlycypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. <i>Psychological Medicine</i> , <b>1979</b> , 9, 377-82	6.9	52
24	Monitoring digoxin therapy: III. How useful are the nomograms?. <i>British Journal of Clinical Pharmacology</i> , <b>1978</b> , 5, 55-64	3.8	20
23	Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. <i>British Journal of Clinical Pharmacology</i> , <b>1977</b> , 4, 213-21	3.8	38
22	Monitoring digoxin therapy: II. Determinants of the apparent volume of distribution. <i>British Journal of Clinical Pharmacology</i> , <b>1977</b> , 4, 223-7	3.8	24
21	Altered distribution of digoxin in renal failure--a cause of digoxin toxicity?. <i>British Journal of Clinical Pharmacology</i> , <b>1976</b> , 3, 1045-51	3.8	43



20	Digoxin therapy: textbooks, theory and practice. <i>British Journal of Clinical Pharmacology</i> , <b>1976</b> , 3, 639-48 <sub>3.8</sub>	14
19	Control Charts and Control Limits in Long-Term Monitoring <sub>90-102</sub>	1
18	Monitoring from the Patient's Perspective: The Social and Psychological Implications <sub>140-157</sub>	1
17	Deaths from cardiovascular disease involving anticoagulants: a systematic synthesis of coroners' case reports	1
16	Preventable deaths from SARS-CoV-2 in England and Wales: a systematic analysis of coroners' case reports from the COVID-19 pandemic	4
15	Monitoring as a Learning and Motivational Tool <sub>123-139</sub>	5
14	Evaluating the Effectiveness and Costs of Monitoring <sub>158-165</sub>	3
13	Oral Anticoagulation Therapy (OAT) <sub>229-244</sub>	2
12	A Framework for Developing and Evaluating a Monitoring Strategy <sub>15-30</sub>	4
11	Monitoring in Osteoarthritis <sub>335-356</sub>	1
10	Biomarkers and Surrogate Endpoints in Monitoring Therapeutic Interventions <sub>48-62</sub>	4
9	Choosing the Best Monitoring Tests <sub>63-74</sub>	3
8	Monitoring Cholesterol-Modifying Interventions <sub>245-253</sub>	
7	Monitoring in Renal Transplantation <sub>286-302</sub>	
6	Monitoring in Pre-Eclampsia <sub>303-312</sub>	
5	Monitoring in Intensive Care <sub>313-324</sub>	
4	Monitoring Intraocular Pressure in Glaucoma <sub>325-334</sub>	
3	Monitoring the Initial Response to Treatment <sub>75-89</sub>	

2	When I use a word . . . . Medical counterfactuals. <i>BMJ, The</i> ,o1267	5.9
1	When I use a word . . . . Counterfactual medical history: the death of Charles II. <i>BMJ, The</i> ,o1345	5.9